Taro Pharmaceutical Industries Ltd. announced that Mr. Dilip Shanghvi has been appointed to its Board of Directors as its Chairman. The company also announced that, effective August 1, 2013, Mr. James Kedrowski will be retiring as its Interim Chief Executive Officer, and that Mr. Kalyanasundaram Subramanian, known in industry circles as Kal Sundaram, has been appointed to serve as Chief Executive Officer of the company. Mr. Kedrowski will continue to serve as a member of the company's Board of Directors.

Mr. Sundaram, while remaining on Taro's board, relinquished the position of Chairman in light of Israeli legal restrictions on simultaneously holding the chairman and CEO position of an Israeli public company. Taro's board addressed this matter by appointing Mr. Dilip Shanghvi as a director to fill the vacancy left by Mr. Aalok Shanghvi's resignation from the board and to serve the board as its Chairman, a position Mr. Dilip Shanghvi had previously held from September 2010 until his resignation from the board in April 2012. Mr. Sundaram became a member and Chairman of Taro's Board of Directors in April 2012.

He was the Chief Executive Officer of Sun Pharmaceutical Industries Ltd. from April 2010 to April 2012.